PodPitch
PodcastsRank #2774
Artwork for BioCentury This Week

BioCentury This Week

BioCentury
Share:
Life SciencesPodcastsScienceBusinessEN-USunited-statesSeveral times per week
4.8 / 5
BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.
Top 5.5% by pitch volume (Rank #2774 of 50,000)Data updated Feb 10, 2026

Key Facts

Publishes
Several times per week
Episodes
358
Founded
N/A
Category
Life Sciences
Number of listeners
Private
Hidden on public pages

Listen to this Podcast

AppleSpotify
EpisodesMetricsListenersContactsSimilarFAQs
PreviousStrategy SimplifiedRank #2773NextThe Medical Sales PodcastRank #2775
Pitch this podcast
Get the guest pitch kit.
Book a quick demo to unlock the outreach details you actually need before you hit send.
  • Verified contact + outreach fields
  • Exact listener estimates (not just bands)
  • Reply rate + response timing signals
10 minutes. Friendly walkthrough. No pressure.
Book a demo
Public snapshot
Audience: 4K–8K / month
Canonical: https://podpitch.com/podcasts/biocentury-this-week
Cadence: Active weekly
Reply rate: Under 2%

Latest Episodes

Back to top

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Tue Feb 03 2026

Listen

RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases. The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies. Dig into the BioCentury’s catalyst picks and the new China policy below • 2026 Catalysts: The rise of RNAi • 2026 Cardiovascular Catalysts: Lp(a) on the Horizon • 2026 Obesity Catalysts: Launches, readouts and challengers • 2026 Catalysts: Breakthrough progress in renal disease • AZ signals all-in on obesity via CSPC deal for $1.2B up front • China’s orphan drug exclusivity could bolster market, incentivize development View full story: https://www.biocentury.com/article/658286 00:00 - Introduction 02:28 - RNAi and Antisense Therapies 06:37 - Neuromuscular and Musculoskeletal 10:33 - Renal Disease Catalysts 22:26 - China's New Orphan Rules To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

More

RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases. The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies. Dig into the BioCentury’s catalyst picks and the new China policy below • 2026 Catalysts: The rise of RNAi • 2026 Cardiovascular Catalysts: Lp(a) on the Horizon • 2026 Obesity Catalysts: Launches, readouts and challengers • 2026 Catalysts: Breakthrough progress in renal disease • AZ signals all-in on obesity via CSPC deal for $1.2B up front • China’s orphan drug exclusivity could bolster market, incentivize development View full story: https://www.biocentury.com/article/658286 00:00 - Introduction 02:28 - RNAi and Antisense Therapies 06:37 - Neuromuscular and Musculoskeletal 10:33 - Renal Disease Catalysts 22:26 - China's New Orphan Rules To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Key Metrics

Back to top
Pitches sent
63
From PodPitch users
Rank
#2774
Top 5.5% by pitch volume (Rank #2774 of 50,000)
Average rating
4.8
Ratings count may be unavailable
Reviews
3
Written reviews (when available)
Publish cadence
Several times per week
Active weekly
Episode count
358
Data updated
Feb 10, 2026
Social followers
17.4K

Public Snapshot

Back to top
Life SciencesPodcastsScienceBusiness
Country
United States
Language
EN-US
Language (ISO)
Release cadence
Several times per week
Latest episode date
Tue Feb 03 2026

Audience & Outreach (Public)

Back to top
Audience range
4K–8K / month
Public band
Reply rate band
Under 2%
Public band
Response time band
30+ days
Public band
Replies received
1–5
Public band

Public ranges are rounded for privacy. Unlock the full report for exact values.

Presence & Signals

Back to top
Social followers
17.4K
Contact available
Yes
Masked on public pages
Sponsors detected
No
Guest format
Yes

Social links

No public profiles listed.

Demo to Unlock Full Outreach Intelligence

We publicly share enough context for discovery. For actionable outreach data, unlock the private blocks below.

Audience & Growth
Demo to unlock
Monthly listeners49,360
Reply rate18.2%
Avg response4.1 days
See audience size and growth. Demo to unlock.
Contact preview
s***@hidden
Get verified host contact details. Demo to unlock.
Sponsor signals
Demo to unlock
Sponsor mentionsLikely
Ad-read historyAvailable
View sponsorship signals and ad read history. Demo to unlock.
Book a demo

How To Pitch BioCentury This Week

Back to top

Want to get booked on podcasts like this?

Become the guest your future customers already trust.

PodPitch helps you find shows, draft personalized pitches, and hit send faster. We share enough public context for discovery; for actionable outreach data, unlock the private blocks.

  • Identify shows that match your audience and offer.
  • Write pitches in your voice (nothing sends without you).
  • Move from “maybe later” to booked interviews faster.
  • Unlock deeper outreach intelligence with a quick demo.

This show is Rank #2774 by pitch volume, with 63 pitches sent by PodPitch users.

Book a demoBrowse more shows10 minutes. Friendly walkthrough. No pressure.

Reviews

Back to top
4.8 / 5
RatingsN/A
Written reviews3

We summarize public review counts here; full review text aggregation is not shown on PodPitch yet.

Frequently Asked Questions About BioCentury This Week

Back to top

What is BioCentury This Week about?

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

How often does BioCentury This Week publish new episodes?

Several times per week

How many listeners does BioCentury This Week get?

PodPitch shows a public audience band (like "4K–8K / month"). Book a demo to unlock exact audience estimates and how we calculate them.

How can I pitch BioCentury This Week?

Use PodPitch to access verified outreach details and pitch recommendations for BioCentury This Week. Start at https://podpitch.com/try/1.

Which podcasts are similar to BioCentury This Week?

This page includes internal links to similar podcasts. You can also browse the full directory at https://podpitch.com/podcasts.

How do I contact BioCentury This Week?

Public pages only show a masked contact preview. Book a demo to unlock verified email and outreach fields.

Quick favor for your future self: want podcast bookings without the extra mental load? PodPitch helps you find shows, draft personalized pitches, and hit send faster.

Book a demoBrowse more shows